ncRNA basic information
ncRNA ID:
MI0000298
ncRNA Database:
miRBase
ncRNA Name:
miR-221
ncRNA Type:
miRNA
ncRNA Expression:
down-regulated
ncRNA Method:
RT-qPCR
ncRNA Target Gene:
TIMP3
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00997 (APRD00185, DB05331, DB05847)
Drug Name:
Doxorubicin
Drug Method:
In the present study, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to assess miR-221 expression in OSCC cells in response to doxorubicin treatment. In addition, the SCC4 and SCC9 OSCC cell lines were transfected with anti-miR-221 oligonucleotides and cell viability and apoptosis following doxorubicin treatment were evaluated using an MTT assay and Annexin V-fluorescein isothiocyanate/Hoechst double staining, respectively. The mRNA and protein expression levels of tissue inhibitor of metalloproteinase-3 (TIMP3) in anti-miR-221-transfected cells were assessed using RT-qPCR and western blot analysis, respectively. Furthermore, a luciferase reporter assay was performed to investigate whether TIMP3 may be a direct target gene of miR-221. To explore the roles of TIMP3 in miR-221-mediated cell responses, TIMP3 expression was silenced following transfection with TIMP3-targeting small interfering (si)RNA in cells overexpressing miR-221, and cell viability and apoptosis in response to doxorubicin treatment were measured.
Drug Response:
sensitive
Cancer basic information
Cancer:
oral squamous cell carcinoma
Tissue/Cell:
cell line ( SCC4,SCC9 )
Other information
Title:
Oral squamous cell carcinoma cells are resistant to doxorubicin through upregulation of miR-221.
Journal:
Mol Med Rep
Published:
2017
PubMed ID:
28677788